Nevro (NYSE:NVRO) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Nevro (NYSE:NVRO) in a report released on Wednesday morning. The brokerage issued a hold rating on the medical equipment provider’s stock.

A number of other analysts have also commented on NVRO. Wells Fargo & Company reduced their price objective on shares of Nevro from $5.00 to $4.00 and set an “equal weight” rating for the company in a research note on Wednesday, December 11th. Piper Sandler raised shares of Nevro from a “neutral” rating to an “overweight” rating and reduced their price objective for the company from $6.00 to $5.85 in a research note on Friday, February 7th. Jefferies Financial Group raised shares of Nevro from an “underperform” rating to a “hold” rating and upped their price objective for the company from $4.50 to $5.85 in a research note on Monday, February 10th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $7.00 target price on shares of Nevro in a report on Tuesday, November 12th. Finally, Citigroup dropped their target price on Nevro from $6.00 to $5.00 and set a “neutral” rating on the stock in a report on Wednesday, December 11th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat, Nevro has an average rating of “Hold” and an average price target of $6.43.

Nevro Price Performance

NVRO stock opened at $5.73 on Wednesday. The company has a current ratio of 5.02, a quick ratio of 3.76 and a debt-to-equity ratio of 0.67. Nevro has a one year low of $3.16 and a one year high of $15.98. The firm has a market capitalization of $214.71 million, a PE ratio of -3.03 and a beta of 0.91. The firm has a 50-day moving average of $4.66 and a two-hundred day moving average of $4.92.

Hedge Funds Weigh In On Nevro

Hedge funds have recently added to or reduced their stakes in the company. Amundi acquired a new position in Nevro in the fourth quarter worth approximately $30,000. Oxford Asset Management LLP acquired a new position in Nevro in the fourth quarter worth approximately $39,000. Corton Capital Inc. acquired a new position in Nevro in the fourth quarter worth approximately $43,000. Headlands Technologies LLC acquired a new position in Nevro in the fourth quarter worth approximately $45,000. Finally, Ieq Capital LLC acquired a new position in Nevro in the fourth quarter worth approximately $46,000. Institutional investors and hedge funds own 95.52% of the company’s stock.

Nevro Company Profile

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.